OncoMatch/Clinical Trials/NCT06930755
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Is NCT06930755 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including NMS-03305293 and Topotecan for ovarian cancer.
Treatment: NMS-03305293 · Topotecan — This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Excluded: BRCA1 mutation
Excluded: BRCA2 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: evidence based local standards of care
failed all evidence based local standards of care as per Investigator judgment
Cannot have received: PARP inhibitor
Exception: outside of approved indication and schedules
Prior therapy with PARP inhibitor, outside of approved indication and schedules
Cannot have received: topoisomerase inhibitor
Prior therapy with topoisomerase inhibitors including payloads of Antibody-Drug Conjugates (ADCs)
Cannot have received: wide-field radiotherapy
Exception: affecting at least 20 percent of the bone marrow
Patients with prior wide-field radiotherapy (RT) affecting at least 20 percent of the bone marrow
Cannot have received: anti-tumor treatment
Exception: within 2 weeks prior to treatment start or 5 half-lives, whichever is longer
Prior anti-tumor treatment within 2 weeks prior to treatment start or 5 half-lives, whichever is longer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- OSF Saint Francis Medical Center · Peoria, Illinois
- Washington University School of Medicine in St. Louis · St Louis, Missouri
- Penn Medicine - Perelman Center for Advanced Medicine · Philadelphia, Pennsylvania
- Tennessee Oncology · Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify